277 related articles for article (PubMed ID: 12478329)
1. Efficacy and tolerability of once-daily telithromycin compared with high-dose amoxicillin for treatment of community-acquired pneumonia.
Hagberg L; Torres A; van Rensburg D; Leroy B; Rangaraju M; Ruuth E
Infection; 2002 Dec; 30(6):378-86. PubMed ID: 12478329
[TBL] [Abstract][Full Text] [Related]
2. Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia.
Tellier G; Niederman MS; Nusrat R; Patel M; Lavin B
J Antimicrob Chemother; 2004 Aug; 54(2):515-23. PubMed ID: 15269191
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of once-daily oral telithromycin compared with clarithromycin for the treatment of community-acquired pneumonia in adults.
Mathers Dunbar L; Hassman J; Tellier G
Clin Ther; 2004 Jan; 26(1):48-62. PubMed ID: 14996517
[TBL] [Abstract][Full Text] [Related]
4. Clinical and bacteriologic efficacy of telithromycin in patients with bacteremic community-acquired pneumonia.
Carbon C; van Rensburg D; Hagberg L; Fogarty C; Tellier G; Rangaraju M; Nusrat R
Respir Med; 2006 Apr; 100(4):577-85. PubMed ID: 16376537
[TBL] [Abstract][Full Text] [Related]
5. Telithromycin in the treatment of community-acquired pneumonia: a pooled analysis.
Hagberg L; Carbon C; van Rensburg DJ; Fogarty C; Dunbar L; Pullman J
Respir Med; 2003 Jun; 97(6):625-33. PubMed ID: 12814146
[TBL] [Abstract][Full Text] [Related]
6. Telithromycin 800 mg once daily for seven to ten days is an effective and well-tolerated treatment for community-acquired pneumonia.
Carbon C; Moola S; Velancsics I; Leroy B; Rangaraju M; Decosta P
Clin Microbiol Infect; 2003 Jul; 9(7):691-703. PubMed ID: 12925111
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of telithromycin 800 mg once daily for 7 days in community-acquired pneumonia: an open-label, multicenter study.
Fogarty CM; Patel TC; Dunbar LM; Leroy BP
BMC Infect Dis; 2005 May; 5():43. PubMed ID: 15927060
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and tolerability of telithromycin for 5 or 10 days vs amoxicillin/clavulanic acid for 10 days in acute maxillary sinusitis.
Luterman M; Tellier G; Lasko B; Leroy B
Ear Nose Throat J; 2003 Aug; 82(8):576-80, 82-4, 586 passim. PubMed ID: 14503094
[TBL] [Abstract][Full Text] [Related]
9. Comparison of hospitalization rates in patients with community-acquired pneumonia treated with 10 days of telithromycin or clarithromycin.
Niederman MS; Chang JR; Stewart J; Nusrat R; Nieman RB
Curr Med Res Opin; 2004 May; 20(5):749-56. PubMed ID: 15140342
[TBL] [Abstract][Full Text] [Related]
10. Comparison of hospitalization rates in patients with community-acquired pneumonia treated with telithromycin for 5 or 7 days or clarithromycin for 10 days.
Tellier G; Chang JR; Asche CV; Lavin B; Stewart J; Sullivan SD
Curr Med Res Opin; 2004 May; 20(5):739-47. PubMed ID: 15140341
[TBL] [Abstract][Full Text] [Related]
11. Hospitalization rates among patients with community-acquired pneumonia treated with telithromycin vs clarithromycin: results from two randomized, double-blind, clinical trials.
Niederman MS; Chang JR; Stewart J; Asche CV; Lavin B; Nusrat R; Sullivan SD
Curr Med Res Opin; 2004 Jul; 20(7):969-80. PubMed ID: 15265241
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and tolerability of 5-day, once-daily telithromycin compared with 10-day, twice-daily clarithromycin for the treatment of group A beta-hemolytic streptococcal tonsillitis/pharyngitis: a multicenter, randomized, double-blind, parallel-group study.
Quinn J; Ruoff GE; Ziter PS
Clin Ther; 2003 Feb; 25(2):422-43. PubMed ID: 12749505
[TBL] [Abstract][Full Text] [Related]
13. Clinical management of respiratory tract infections in the community: experience with telithromycin.
Quintiliani R
Infection; 2001 Dec; 29 Suppl 2():16-22. PubMed ID: 11785852
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and tolerability of once-daily oral therapy with telithromycin compared with trovafloxacin for the treatment of community-acquired pneumonia in adults.
Pullman J; Champlin J; Vrooman PS
Int J Clin Pract; 2003 Jun; 57(5):377-84. PubMed ID: 12846341
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of telithromycin in community-acquired pneumonia.
Van Rensburg DJ; Matthews PA; Leroy B
Curr Med Res Opin; 2002; 18(7):397-400. PubMed ID: 12487505
[TBL] [Abstract][Full Text] [Related]
16. Community-acquired respiratory tract infections caused by resistant pneumococci: clinical and bacteriological efficacy of the ketolide telithromycin.
Fogarty CM; Kohno S; Buchanan P; Aubier M; Baz M
J Antimicrob Chemother; 2003 Apr; 51(4):947-55. PubMed ID: 12654763
[TBL] [Abstract][Full Text] [Related]
17. A pooled analysis of telithromycin in the treatment of community-acquired respiratory tract infections in adults.
Carbon C
Infection; 2003 Oct; 31(5):308-17. PubMed ID: 14556055
[TBL] [Abstract][Full Text] [Related]
18. Clinical efficacy and time to symptom resolution of 5-day telithromycin versus 10-day amoxicillin-clavulanate in the treatment of acute bacterial sinusitis.
Desrosiers M; Ferguson B; Klossek JM; Drugeon H; Mösges R
Curr Med Res Opin; 2008 Jun; 24(6):1691-702. PubMed ID: 18559163
[TBL] [Abstract][Full Text] [Related]
19. Telithromycin is as effective as amoxicillin/clavulanate in acute exacerbations of chronic bronchitis.
Aubier M; Aldons PM; Leak A; McKeith DD; Leroy B; Rangaraju M; Bienfait-Beuzon C
Respir Med; 2002 Nov; 96(11):862-71. PubMed ID: 12418583
[TBL] [Abstract][Full Text] [Related]
20. Bacteriological efficacy of 5-day therapy with telithromycin in acute maxillary sinusitis.
Buchanan P; Roos K; Tellier G; Rangaraju M; Leroy B
Int J Antimicrob Agents; 2005 Mar; 25(3):237-46. PubMed ID: 15737519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
